NR4A1 and breast carcinoma: Moreover, as alpelisib—a PIK3CA inhibitor—became FDA-approved last year for PIK3CA-altered, hormone receptor–positive advanced breast cancer,40 this study reveals that 12% of early-onset AC cases could potentially benefit from targeting this variation and merits further study.